The Case of the Malignant Cohort
When evaluating PE risk in oncology patients, don't assume the standard YEARS protocol or D-dimer threshold is perfectly reliable; its performance seems questionable here. Given this uncertainty, consider using clinical judgment alongside established scoring systems rather than relying solely on a negative D-dimer to rule out PE in these high-risk individuals.
This piece dives into the application of the YEARS protocol for ruling out pulmonary embolism (PE) using a D-dimer threshold, specifically flagging concerns regarding its utility in patients with active malignancy. While the Hydra trial demonstrated comparable 90-day mortality rates between different diagnostic pathways, the authors raise flags about the YEARS score's ability to accurately stratify risk within this particular cancer cohort compared to what might be expected from other literature. The core argument suggests that because the YEARS approach appears less robust for this group, relying solely on the D-dimer cutoff in cancer patients warrants caution. It’s a good reminder that diagnostic algorithms need careful vetting when applied outside their primary indication.